Join the Vitrakvi group to help and get support from people like you.
Vitrakvi News
U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors
WHIPPANY, N.J.--(BUSINESS WIRE) April 10, 2025 --Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Vitrakvi® (larotrectinib), a first-in-class TRK ...
FDA Medwatch Alert: Bayer Issues Voluntary Recall Nationwide of Vitrakvi (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination
November 17, 2023 – WHIPPANY, N.J., Bayer is voluntarily recalling one lot of Vitrakvi® (larotrectinib) Oral Solution 20 mg/mL in 100mL glass bottles to the consumer/user level. The product is being r...
FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers
November 26, 2018 – The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific...